Indian drugmaker denies syrup exported to Liberia is toxic

Published On 2023-06-22 10:30 GMT   |   Update On 2023-06-22 10:31 GMT
Advertisement

New Delhi: An Indian maker of a paracetamol syrup that Nigerian authorities have found toxic told Reuters on Tuesday that tests by a private Indian laboratory found them of "standard quality", as Indian authorities launch their own investigation.

Nigeria's National Agency for Food and Drugs Administration and Control (NAFDAC) said in an alert last week that samples of the Indian-made paracetamol suspension, Para Clear, exported to Liberia last year contained the toxin ethylene glycol. It also failed the requirement for "acute oral toxicity with five deaths of the laboratory animals recorded", the agency said.

Many Indian-made drugs have been found to have contained ethylene glycol and similar toxin diethylene glycol since last year, which the World Health Organization (WHO) have linked to the deaths of dozens of children in Gambia and Uzbekistan. The toxins are commonly used in brake fluid and other products not meant for human consumption.

"There is no possibility at all of finding ethylene glycol or diethylene glycol in our product," said Jaimik Patel, a director at Curis Lifesciences, based in the western Indian city of Ahmedabad and whose products were sold in Liberia.

"We are challenging the claim that our product was toxic."

A test of a sample of the medicine conducted by privately run Vaibhav Analytical Services in Ahmedabad on Saturday, and seen by Reuters, said the syrup had less than 0.1% of ethylene glycol and diethylene glycol.

"The sample referred ... IS OF standard quality," the test report from the Ahmedabad-based laboratory said.

Trace amounts of less than 0.1% of ethylene glycol and diethylene glycol in medicines are not considered toxic, according to the WHO.

NAFDAC, in its alert, did not give a toxicity concentration figure but said ethylene glycol was a "toxic substance that is not expected in product formulations". It did not immediately respond to a request for comment.

Patel said officials from India's federal drug regulator, the Central Drugs Standard Control Organisation, also picked up the sample for their own investigation. He said Curis had shared the test results and other documents with the regulator and the WHO.

Mumbai-based drug exporter Synercare told Reuters it had shipped two batches of nearly 20,000 Curis-made Para Clear bottles each to Liberia in October. Synercare's exports manager Dipesh Ajmera and Patel said Liberian authorities have now revoked the permission for the sale of all Curis products, including painkillers paracetamol and ibuprofen and antibiotic medication azithromycin.

Ajmera said Liberian authorities were set to destroy one batch of the paracetamol syrup last year as the drug's colour did not match that of a comparable product. The paracetamol suspension was supposed to be reddish brown but on physical verification, it was found to be reddish pink, Ajmera said.

Keturah Smith-Chineh, head of the Liberia Medicines and Health Products Regulatory Authority, told Reuters the syrups were to be incinerated because of the colour variation but it was tested in Nigeria at the request of the medicine's local importer.

"We plan to incinerate all the ... stock that came into Liberia," she said. "There are two other child medications from that manufacturer and we are working on recalling them."

Read also: Gambia probes suspected paracetamol syrup link to dozens of child deaths

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News